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Abstract 
Background and Aim: Recently, the association of the dysfunction of programmed cell 
death (PD)-1 expressed on activated lymphocytes with the pathogenesis of autoimmune 
hepatitis (AIH) has been speculated. This study aimed to investigate the association of 
serum anti-PD-1 antibodies with clinical characteristics of type 1 AIH.  
Methods: Serum samples before the initiation of prednisolone treatment were obtained 
from 52 type 1 AIH patients, 24 patients with drug-induced liver injury (DILI), 30 
patients with acute viral hepatitis (AVH), 11 patients with primary sclerosing cholangitis 
(PSC), and 62 healthy volunteers. Titers of serum anti-PD-1 antibodies were measured 
by indirect enzyme-linked immunosorbent assay. The cut-off level was represented by a 
mean absorbance + 2 standard deviations in healthy volunteers. 
Results: Prevalence of serum anti-PD-1 antibodies was 63% in type 1 AIH patients, 8% 
in DILI patients, 13% in AVH patients, 18% in PSC patients, and 3% in healthy 
volunteers. In type 1 AIH patients, titers of serum anti-PD-1 antibodies were correlated 
with serum levels of bilirubin (r = 0.31, P = 0.030) and alanine aminotransferase (r = 
0.31, P = 0.027) but not serum immunoglobulin G levels. Positivity for serum ani-PD-1 
antibodies was associated with the later normalization of serum alanine 
aminotransferase levels after the initiation of prednisolone and the disease relapse.  
Conclusions: Serum anti-PD-1 antibodies would be useful for the discrimination of 
type 1 AIH from DILI, AVH and PSC as an auxiliary diagnostic marker. Furthermore, 
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anti-PD-1 antibodies may be associated with clinical characteristics of type 1 AIH. 
 
Keywords: Acute viral hepatitis; Autoimmune hepatitis; Drug-induced liver injury; 
Primary sclerosing cholangitis; Programmed cell death-1.
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Introduction 
Autoimmune hepatitis (AIH) is a progressive, autoimmune liver disease characterized 
by histological interface hepatitis, hypergammaglobulinemia, and circulating 
autoantibodies.
1
 However, the pathogenesis of AIH has not been fully revealed yet, and 
the diagnosis is made based on the scoring systems for lack of specific diagnostic 
markers for AIH.
2,3
  
Recently, co-stimulatory molecules with inhibitory properties expressed on 
activated T and B cells are revealed to be possibly associated with the pathogenesis of 
AIH. Programmed cell death (PD)-1 deficient mice thymectomized 3 days after birth 
develop massive hepatic necrosis with the appearance of serum anti-nuclear antibody 
(ANA).
4
 Furthermore, a clinical trial using anti-PD-1 antibody as immunotherapeutic 
agent for advanced cancer shows the development of hepatitis, which required 
corticosteroid treatment, as adverse event.
5
 Anti-PD-1 antibodies enhance allogeneic T 
cell proliferation.
6
 Dysfunction of PD-1 may activate auto-reactive T cells and result in 
the development of autoimmune diseases. 
Thus, we speculated that anti-PD-1 antibodies might exist in sera of type 1 AIH 
patients. This study aimed to confirm the presence of anti-PD-1 antibodies in sera of 
type 1 AIH patients and to investigate the usefulness of serum anti-PD-1 antibody for 
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the discrimination of type 1 AIH from drug-induced liver injury (DILI), acute viral 
hepatitis (AVH), and primary sclerosing cholangitis (PSC), and the association of serum 
anti-PD-1 antibodies with the clinical features of type 1 AIH. 
 
Methods 
Ethics. This study complied with the Declaration of Helsinki and was approved by the 
Institutional Review Board at Okayama University Graduate School of Medicine, 
Dentistry, and Pharmaceutical Sciences. Serum samples and data were collected after 
each subject provided written informed consent. 
 
Patients and serum samples. Serum samples before the initiation of corticosteroid 
treatment were obtained from 52 type 1 AIH patients, 24 DILI patients, 30 AVH patients, 
and 11 PSC patients. Thirty AVH patients consisted of 7 patients with acute hepatitis A, 
21 patients with acute hepatitis B, and 2 patients with acute hepatitis C. Moreover, 62 
serum samples from healthy volunteers were collected. Clinical characteristics of study 
population are shown in Table 1. Serum samples were stored -30°C until use. 
All type 1 AIH patients underwent liver biopsy. All of type 1 AIH patients, DILI 
patients and PSC patients were seronegative for immunoglobulin M (IgM) antibody to 
hepatitis A virus, IgM antibody to hepatitis B core antigen, hepatitis B surface antigen, 
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and hepatitis C virus RNA identifiable by nested reverse transcription-polymerase chain 
reaction. Type 1 AIH was diagnosed based on the revised scoring system proposed by 
International Autoimmune Hepatitis Group.
2
 None of type 1 AIH patients were positive 
for serum anti-liver kidney microsomal-1 autoantibodies. DILI was diagnosed based on 
the diagnostic criteria of the Digestive Disease Week-Japan 2004 workshop,
7
 which 
usefulness in the diagnosis of DILI has been confirmed by the study with large sample 
size.
8
 A diagnosis of hepatitis A, B and C was made based on the presence of IgM 
antibody to hepatitis A virus, IgM antibody to hepatitis B core antigen, and hepatitis C 
virus RNA, respectively. The diagnosis of PSC was made according to accepted criteria; 
typical cholangiographic findings or histological findings of cholangitis in combination 
with biochemical and clinical findings.
9
 
Liver biopsy in type 1 AIH patients was performed before or just after 
commencing the initial treatment. Liver biopsy specimens were evaluated by two 
pathologists (YM, KY) and diagnosed as acute or chronic hepatitis.
10
 Liver biopsy 
specimens diagnosed as chronic hepatitis underwent histological staging based on the 
classification of Desmet and colleagues.
11
 
 
Treatment for type 1 AIH. As initial treatment, 43 patients (83%) received 
7 
 
prednisolone (PSL) treatment (20-40 mg/day), and 4 patients (8%) did monotherapy of 
ursodeoxycholic acid (UDCA). In the remaining 5 patients (9%), initial treatment was 
unknown because they were transferred to other hospitals without follow-up. Initial 
treatment was continued until the normalization of serum alanine aminotransferase 
(ALT) levels (30 IU/l or lower). 
After the normalization of serum ALT levels, PSL was tapered by 2.5–5 mg every 
1 or 2 weeks to a maintenance dose of 10 mg/day or less. PSL was halted when normal 
levels of serum ALT continued at the maintenance dose for more than 2 years. 
Each patient underwent a comprehensive clinical review and physical 
examination at presentation and each follow-up visit. Conventional laboratory blood 
tests were performed every 1–2 months. 
 
Criteria for relapse in type 1 AIH. Relapse was defined as an increase in serum ALT 
level to more than twofold of the upper normal limit (higher than 60 IU/l), following the 
normalization of serum ALT level with medical treatment. 
 
Peripheral blood mononuclear cell isolation and activation. Approximately 30 ml of 
blood was obtained from a healthy volunteer in heparinized tubes. Purified peripheral 
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blood mononuclear cells (PBMCs) were obtained by Ficoll-Hypaque density gradient 
centrifugation (GE Healthcare). PBMCs were resuspended in RPMI 1640 culture 
medium (Sigma-Aldrich) supplemented with 5% heat-inactivated human AB serum (MP 
Biomedicals), 2 mM L-glutamine (Sigma-Aldrich), and 1% penicillin/streptomycin 
solution (Sigma-Aldrich). CD3/CD28 Dynabeads (Life technologies) were added to 
obtain a bead-to-cell ratio of 1:1. The cultures were incubated for 7 days at 37 °C in 5% 
CO2. 
 
Activated PBMC lysate. Activated PBMCs were washed twice in phosphate-buffered 
saline (PBS), resuspended in 500 μl of Pierce® IP lysis buffer (Pierce Biotechnology), 
and homogenized using FastPrep®-24 (MP Biomedicals). Lysates were cleared by a 
10-min centrifugation at 10,000 × g at 4°C. Protein concentration was 2.8 μg/μl by 
using the Protein Assay Dye Reagent Concentrate (Bio-Rad). 
 
Co-immunoprecipitation. Briefly, 200 μl of human sera diluted 1:10 in PBS with 
0.02 % Tween 20 were incubated with Dynabeads Protein G (Invitrogen Dynal AS) for 
1 hour at room temperature. The beads were washed with PBS and incubated with 200 
μl PBS containing 20 μg activated PBMC lysate for 1 hour at room temperature. Beads 
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were then washed with PBS, and retained proteins were eluted with 2 x SDS sample 
buffer (20% glycerol, 4% SDS, 125mM tris-HCl pH6.8, 12% 2-mercaptoethanol, 
0.004% bromophenol blue). 
 
Western blot. Proteins were separated by SDS-polyacrylamide gel electrophoresis. The 
separated components were electroblotted onto an Immobilon-P polyvinylidene 
difluoride membrane (Millipore Corporation). Blot membranes were blocked in PVDF 
blocking reagent for Can Get Signal (TOYOBO CO., LTD.). The blots were washed 
with tris-buffered saline with Tween 20 and reacted with a 1:1,000 dilution of 
anti-human PD-1 antibody (R&D Systems) for 1 hour at room temperature, washed and 
then reacted with HRP-conjugated anti-mouse IgG for 1 hour. The blots were then 
developed by ECL (GE Healthcare) according to the manufacturer's instructions. 
 
Indirect enzyme-linked immunosorbent assay. Titers of serum anti-PD-1 antibodies 
were measured by indirect enzyme-linked immunosorbent assay (ELISA) using Protein 
Detector ELISA Kit (Kirkegaard & Perry Laboratories). All serum samples were tested 
in duplicate.  
Briefly, 96-well U-bottom microtiter plates (Greiner Bio-One GmbH) were coated 
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with 100 μl of 1 μg/ml recombinant PD-1 (Abnova) in PBS at room temperature for 1 
hour. Unbound antigen was removed, nonspecific binding sites were blocked by 
incubation with 1% bovine-serum albumin (BSA) in PBS, and the wells were incubated 
with 100 μl of human sera diluted 1:20 in PBS with 1% of BSA for 1 hour. Following 
incubation, the wells were incubated with anti-human IgG diluted 1:1,000 in PBS with 
1% of BSA, covalently linked to alkaline phosphatase, and the reaction was visualized 
by adding 100 μl of a substrate buffer (5-bromo-4-chloro-3-indolyl phosphate/ nitroblue 
tetrazolium). The optical densities at 630 nm were read with a Model 680 microplate 
reader (Bio-Rad Laboratories). In order to avoid inter-plate variability, we used a 
positive serum, assigned it 0.200 OD630nm, and read the optical densities of all samples 
against this positive serum. Intra-assay variability was found to be 8.4%. 
 
Statistical analysis. Statistical analysis was performed using the SPSS statistical 
program. Continuous variables were expressed as median (range). Differences in 
continuous variables were evaluated by the Mann–Whitney U-test between two 
independent samples and the Kruskal–Wallis test among five independent samples. 
Dichotomous variables were compared by the χ2-test. The Spearman correlation 
coefficient was used to evaluate the consistency in the continuous variables between 
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two samples. Cumulative survival curves were analyzed using the Kaplan-Meier 
method, and the differences in the curves were tested using the log-rank test. The 
diagnostic accuracy of each factor was evaluated based on the area under the curve 
(AUC) using receiver operating characteristic (ROC) curve analysis. P-values <0.05 
were considered significant. 
 
Results 
Western blot analysis of serum anti-PD-1 antibody. We performed 
co-immunoprecipitation assay of activated PBMC lysate from a healthy volunteer and 
serum IgG from type 1 AIH patients, followed by western blot analysis (n = 3). Western 
blot analysis showed the protein band stained with anti-human PD-1 antibody (R&D 
Systems) (Fig. 1). This indicates that IgG-isotype antibodies binding to PD-1 molecules 
expressed on activated T cells exist in sera of some type 1 AIH patients. 
 
Titers and prevalence of serum anti-PD-1 antibody. Titers of serum anti-PD-1 
antibodies were significantly higher in type 1 AIH patients {0.101 (0.037-0.539) 
OD630nm} than in DILI patients {0.044 (0.005-0.104) OD630nm}, AVH patients {0.062 
(0.015-0.186) OD630nm}, PSC patients {0.037 (0.020-0.357) OD630nm}, and healthy 
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volunteers {0.033 (0.002-0.144) OD630nm} (Fig. 2). When the cut-off level was 
represented by a mean absorbance + 2 SD in healthy volunteers (= 0.086 OD630nm), 
positivity for serum anti-PD-1 antibodies was shown in 63% of type 1 AIH patients, 8% 
of DILI patients, 13% of AVH patients, 18% of PSC patients, and 3% of healthy 
volunteers.  
 
Serum anti-PD-1 antibody and clinical characteristics. In type 1 AIH patients, titers 
of serum anti-PD-1 antibodies were correlated with serum levels of bilirubin (r = 0.31, P 
= 0.030), aspartate aminotransferase (AST) (r = 0.29, P = 0.042), and ALT (r = 0.31, P = 
0.027); however titers of serum anti-PD-1 antibodies were not correlated with serum 
IgG levels (r = 0.12, P = 0.40). In DILI patients, AVH patients, and PSC patients, titers 
of serum anti-PD-1 antibodies did not correlate with serum levels of bilirubin or AST, 
ALT. 
The association of serum anti-PD-1 antibodies with ANA was analyzed. Type 1 
AIH patients positive for ANA (1:40 or higher) had higher titers {0.113 (0.037-0.539) 
OD630nm versus 0.074 (0.038-0.439) OD630nm; P = 0.041} and higher prevalence (70% 
versus 33%; P = 0.039) of serum anti-PD-1 antibodies than those negative for ANA.  
Anti-smooth muscle cell antibodies (ASMA) was measured in 34 type 1 AIH 
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patients. Of them, 18 patients (53%) were positive for ASMA (1:40 or higher). ASMA 
positivity was not associated with either titers {0.119 (0.041-0.439) OD630nm versus 
0.115 (0.038-0.411) OD630nm; P = 0.97} or prevalence (83% versus 69%; P = 0.32) of 
serum anti-PD-1 antibodies. 
Histologically, of 52 type 1 AIH patients, seven were diagnosed with acute 
hepatitis, and the remaining 45 patients were diagnosed with chronic hepatitis. Patients 
with acute hepatitis showed higher titers of serum anti-PD-1 antibodies than those with 
chronic hepatitis {0.179 (0.076-0.439) OD630nm versus 0.097 (0.037-0.539) OD630nm; P = 
0.016}. Of 7 patients diagnosed with acute hepatitis, 6 (86%) were positive for serum 
anti-PD-1 antibodies. Of 45 patients with chronic hepatitis, 27 showed early stage of 
liver fibrosis (F1 or F2), and the remaining 18 did the advanced stage (F3 or F4); 
however titer of serum anti-PD-1 antibodies {0.101 (0.041-0.539) OD630nm versus 0.093 
(0.037-0.340) OD630nm; P = 0.58} were not differed between patients showing early 
stage of liver fibrosis and those showing the advanced stage. 
 
Serum anti-PD-1 antibody and the diagnosis of type 1 AIH. The AUC of serum 
anti-PD-1 antibody for the discrimination of type 1 AIH from DILI, AVH, PSC, and 
healthy volunteers was 0.88 (95% confidence interval 0.80-0.96; P <0.001), 0.79 (95% 
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confidence interval 0.69-0.89; P <0.001), 0.80 (95% confidence interval 0.60-0.99; P = 
0.002), and 0.93 (95% confidence interval 0.89-0.97; P <0.001), respectively. On the 
other hand, the AUC of ANA for the discrimination of type 1 AIH from DILI and PSC 
was 0.89 (95% confidence interval 0.81-0.96; P <0.001) and 0.91 (95% confidence 
interval 0.84-0.98; P <0.001), respectively. 
When patients positive for serum anti-PD-1 antibodies were diagnosed with type 
1 AIH, the sensitivity, specificity, and positive and negative predictive values in the 
differential diagnosis between type 1 AIH and DILI were 63%, 92%, 94%, and 54%, 
respectively. Furthermore, those in the differential diagnosis between type 1 AIH 
histologically diagnosed with acute hepatitis and DILI were 86%, 92%, 75%, and 96%, 
respectively. 
Similarly, the sensitivity, specificity, and positive and negative predictive values 
in the differential diagnosis between type 1 AIH and AVH were 63%, 87%, 89%, and 
58%, respectively. In addition, those in the differential diagnosis between type 1 AIH 
histologically diagnosed with acute hepatitis and AVH were 86%, 87%, 60%, and 96%, 
respectively. 
In the differential diagnosis between type 1 AIH and PSC, the sensitivity, 
specificity, and positive and negative predictive values were 64%, 82%, 94%, and 32%, 
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respectively. 
  
Serum anti-PD-1 antibody and treatment response. Of 43 patients treated with PSL 
as the initial treatment, 7 were excluded from this analysis because their serum ALT 
level at the time of the initiation of PSL treatment was 30 IU/l or lower. So, in the 
remaining 36 patients, the association of positivity for serum anti-PD-1 antibodies with 
the normalization of serum ALT levels was investigated. There was no difference in 
serum ALT levels before the initiation of PSL treatment between 27 patients positive for 
serum anti-PD-1 antibodies and 9 negative for serum anti-PD-1 antibodies {335 
(59-1783) IU/l versus 214 (59-2161) IU/l; P = 0.49}. Starting dose of PSL was similar 
between the two groups {40 (20-60) mg/day versus 40 (20-50) mg/day; P = 0.80}. The 
normalization of serum ALT levels after the initiation of PSL treatment was later in 
patients positive for serum anti-PD-1 antibodies (Fig. 3, log-rank test: p = 0.024). 
Of 47 patients achieving the normalization of serum ALT levels, 2 were 
transferred to other hospitals within 6 months from the normalization of serum ALT 
levels. So, in the other 45 patients, the association of positivity for serum anti-PD-1 
antibodies with relapse of the disease was investigated. Of the 45 patients, 29 were 
positive for serum anti-PD-1 antibodies. There was no difference in the follow-up 
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duration after the normalization of serum ALT levels between 29 patients positive for 
serum anti-PD-1 antibodies and 16 patients negative for serum anti-PD-1 antibodies 
{89.1 (7.5-173.2) months versus 63.4 (11.4-209.6) months; P = 0.41}. In 19 of 29 
patients (66%) positive for serum anti-PD-1 antibodies and 5 of 16 patients (31%) 
negative for serum anti-PD-1 antibodies, the disease relapsed (P = 0.027). 
 
Discussion 
In type 1 AIH patients, serum IgG levels are shown to be associated with disease 
activity,
12,13
 relapse after drug withdrawal,
14
 and recurrence of the disease after liver 
transplantation.
15
 Serum IgG of type 1 AIH patients may contain some autoantibodies 
associated with the pathogenesis of the disease.  
This study suggests that IgG-isotype PD-1 antibodies exist in sera of some type 1 
AIH patients and that serum anti-PD-1 antibodies may be useful for the discrimination 
of type 1 AIH from DILI, AVH and PSC as an auxiliary diagnostic marker. Furthermore, 
serum anti-PD-1 antibodies were shown to be associated with the disease activity and 
the response to corticosteroid treatment. Patients positive for serum anti-PD-1 
antibodies show severer disease and more frequently relapse. Patients negative for 
serum anti-PD-1 antibodies better respond to corticosteroid treatment. Recently, 
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repeated relapses have been reported to be associated with poor prognosis.
16
 
Measurement of serum anti-PD-1 antibodies before the initiation of corticosteroid 
treatment may be also useful for the prediction of prognosis in type 1 AIH. 
Serum IgG level and ANA are important markers for the diagnosis of type 1 AIH. 
The diagnosis of type 1 AIH showing atypical features such as lower serum IgG levels 
and negativity for ANA is not easy.
17,18
 A recent nationwide survey in Japan revealed 
that approximately 10% of type 1 AIH patients showed histological features of acute 
hepatitis with lower serum IgG levels at presentation.
19,20
 On the other hand, 
approximately 20-30% of general population has been reported to be positive for 
ANA.
21,22
 In this study, 4 of 7 type 1 AIH patients histologically diagnosed with acute 
hepatitis showed serum ANA titers of 1:40 or less, and 3 of these 4 patients were 
positive for serum anti-PD-1 antibodies. And, of 6 patients showing serum IgG levels 
below 2 g/dl and serum ANA titers of 1:40 or less, 3 were positive for serum anti-PD-1 
antibodies. Furthermore, 27 of 40 patients whose serum titers of either ANA or ASMA 
were 1:80 or higher showed positivity for serum anti-PD-1 antibodies, and 6 of 12 
patients whose serum titers of both ANA and ASMA were 1:40 or less showed positivity 
for serum anti-PD-1 antibodies. So, we speculate that serum anti-PD-1 antibodies may 
be useful for the diagnosis of type 1 AIH as an auxiliary diagnostic marker. 
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This study did not show functional effect of serum anti-PD-1 antibodies on 
lymphocytes although several studies have shown the following findings in type 1 AIH 
patients: 1) hyper-responsiveness of CD8
+
 T cells to antigen,
23
 2) apoptosis-resistance in 
CD4
+
 CD25
-
 T cells and CD8
+
 T cells,
24
 3) reduced expression of FOXP3 in CD4
+
 
CD25
+
 T cells,
24,25
 4) decreased number of CD4
+
 CD25
+
 T cells,
23,25
 5) reduced ability 
of CD4
+
 CD25
+
 T cells to regulate CD8
+
 T cells proliferation.
23
 The similar phenomena 
are shown to be developed by using anti-PD-1 antibody. Anti-PD-1 antibody accelerates 
the proliferation of CD8
+
 T cells and enhances the production of IFN-γ, TNF-α and IL-2 
from CD8
+
 T cells.
26
 Furthermore, anti-PD-1 antibodies decrease the number and 
protective effect of CD4
+
 CD25
+
 T cells.
27-29
 In this study, titers of serum anti-PD-1 
antibodies were correlated with serum levels of bilirubin and transaminase in type 1 
AIH patients. Thus, we speculate that anti-PD-1 antibodies may be associated with the 
pathogenesis of type 1 AIH.  
In summary, this study suggests that anti-PD-1 antibodies will exist in sera of 
some type 1 AIH patients, and that serum anti-PD-1 antibodies may be useful for the 
discrimination of type 1 AIH from DILI, AVH and PSC as an auxiliary diagnostic 
marker. Furthermore, anti-PD-1 antibodies may be associated with clinical features of 
type 1 AIH. In order to confirm these findings, further studies are required. The role of 
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anti-PD-1 antibodies in the pathogenesis of type 1 AIH may be worth investigating. 
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Table 1. Clinical characteristics of study population. 
 Type 1 AIH DILI AVH PSC 
Sample size, n 52 24 30 11 
Age, yr 52 (16-84) 41 (14-73) 42 (16-79) 35 (19-68) 
Gender, female (%) 46 (88) 10 (42) 12 (40) 2 (18) 
Laboratory data    
WBC (x10
3
/mm
3
) 5.1 (1.0-11.5) 5.9 (3.5-12.5) 6.3 (3.9-18.6) 5.7 (4.2-9.1) 
Hemoglobin (g/dl) 12.6 (8.3-16.5) 13.3 (11.5-15.9) 14.5 (10.8-18.4) 12.3 (7.8-15.5) 
Platelet (x10
4
/mm
3
) 16.1 (5.6-36.7) 23.9 (10.7-44.0) 18.2 (2.2-33.6) 26.1 (10.3-74.3) 
Bilirubin (mg/dl) 1.2 (0.5-22.6) 1.3 (0.5-26.0) 5.1 (0.8-25.4) 1.3 (0.4-14.8) 
AST (IU/l) 216 (45-2330) 118 (30-3590) 1445 (112-5540) 72 (35-138) 
ALT (IU/l) 229 (33-2161) 205 (38-6170) 2501 (266-7990) 60 (49-293) 
IgG(g/dl) 2.55 (1.34-6.56) 1.33 (0.77-3.15) 1.48 (0.60-2.37) 1.83 (1.30-3.45) 
ANA (%)    
  <1:40 9 (17) 21 (87) ― 11 (100) 
  ≥1:40 and ≤ 1:80 11 (21) 3 (13) ― 0 (0) 
  ≥ 1:160 32 (62) 0 (0) ― 0 (0) 
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Table 1. Continued. 
Healthy P value 
62 ― 
44 (24-78) 0.026 
40 (65) <0.0001 
  
― 0.018 
― 0.0004 
― 0.0073 
― 0.0013 
― <0.0001 
― <0.0001 
― <0.0001 
― <0.0001 
―  
―  
―  
AIH, autoimmune hepatitis; ALT, alanine aminotransferase; ANA, anti-nuclear 
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antibody; AST, aspartate aminotransferase; AVH, acute viral hepatitis; DILI, 
drug-induced liver injury; IgG, immunoglobulin G; WBC, white blood cell; PSC, 
primary sclerosing cholangitis.  
P value is based on the statistical analysis by the Kruskal–Wallis test assessing overall 
group differences. 
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Figure legends 
Figure 1. Identification of serum anti-programmed cell death-1 antibodies by western 
blot analysis. Serum anti-programmed cell death-1 antibodies in type 1 autoimmune 
hepatitis patients were identified by co-immunoprecipitation of activated peripheral 
blood mononuclear cell lysate and serum immunoglobulin G followed by western blot 
analysis (n = 3). Activated peripheral blood mononuclear cell lysate was used as 
positive control.  
Figure 2. Titers of serum anti-programmed cell death-1 antibodies in study populations. 
Closed circles show positivity for serum anti-programmed cell death-1 antibodies. Open 
circles show negativity for serum anti-programmed cell death-1 antibodies. 
Figure 3. Cumulative incident rates of the normalization of serum alanine 
aminotransferase levels after the initiation of prednisolone treatment. 
